WO2021173471A1 - Anti-human cd19 antibodies - Google Patents
Anti-human cd19 antibodies Download PDFInfo
- Publication number
- WO2021173471A1 WO2021173471A1 PCT/US2021/018989 US2021018989W WO2021173471A1 WO 2021173471 A1 WO2021173471 A1 WO 2021173471A1 US 2021018989 W US2021018989 W US 2021018989W WO 2021173471 A1 WO2021173471 A1 WO 2021173471A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- antibody
- human
- nucleic acid
- cell
- Prior art date
Links
- 238000000034 method Methods 0.000 claims abstract description 23
- 239000000203 mixture Substances 0.000 claims abstract description 21
- 101100383038 Homo sapiens CD19 gene Proteins 0.000 claims abstract description 16
- 241000282414 Homo sapiens Species 0.000 claims description 116
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 110
- 150000007523 nucleic acids Chemical class 0.000 claims description 110
- 210000004027 cell Anatomy 0.000 claims description 92
- 239000013598 vector Substances 0.000 claims description 79
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 72
- 230000000779 depleting effect Effects 0.000 claims description 45
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 40
- 102000039446 nucleic acids Human genes 0.000 claims description 37
- 108020004707 nucleic acids Proteins 0.000 claims description 37
- 208000035475 disorder Diseases 0.000 claims description 23
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 14
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 208000023275 Autoimmune disease Diseases 0.000 claims description 11
- 201000006417 multiple sclerosis Diseases 0.000 claims description 10
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 8
- XGWFJBFNAQHLEF-UHFFFAOYSA-N 9-anthroic acid Chemical compound C1=CC=C2C(C(=O)O)=C(C=CC=C3)C3=CC2=C1 XGWFJBFNAQHLEF-UHFFFAOYSA-N 0.000 claims description 7
- 201000011152 Pemphigus Diseases 0.000 claims description 7
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 7
- 206010047115 Vasculitis Diseases 0.000 claims description 7
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 7
- 206010028417 myasthenia gravis Diseases 0.000 claims description 7
- 201000001976 pemphigus vulgaris Diseases 0.000 claims description 7
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 7
- 208000008795 neuromyelitis optica Diseases 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 3
- 239000001963 growth medium Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 abstract description 71
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 abstract description 69
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 28
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 28
- 241000699670 Mus sp. Species 0.000 description 28
- 230000027455 binding Effects 0.000 description 28
- 210000004369 blood Anatomy 0.000 description 28
- 239000008280 blood Substances 0.000 description 28
- 108020004414 DNA Proteins 0.000 description 21
- 241000699666 Mus <mouse, genus> Species 0.000 description 20
- 201000010099 disease Diseases 0.000 description 17
- 241000282567 Macaca fascicularis Species 0.000 description 16
- 239000012636 effector Substances 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 14
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 14
- 229940121470 obexelimab Drugs 0.000 description 14
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 13
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 13
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 13
- 239000002953 phosphate buffered saline Substances 0.000 description 13
- 238000000338 in vitro Methods 0.000 description 12
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 12
- 239000000427 antigen Substances 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 108091007433 antigens Proteins 0.000 description 11
- 238000003556 assay Methods 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 10
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 9
- 230000004913 activation Effects 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 9
- 230000004069 differentiation Effects 0.000 description 9
- 231100000673 dose–response relationship Toxicity 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 102000001708 Protein Isoforms Human genes 0.000 description 8
- 108010029485 Protein Isoforms Proteins 0.000 description 8
- 206010012601 diabetes mellitus Diseases 0.000 description 8
- 201000002491 encephalomyelitis Diseases 0.000 description 8
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 8
- 230000035899 viability Effects 0.000 description 8
- 230000004663 cell proliferation Effects 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 239000012091 fetal bovine serum Substances 0.000 description 7
- 229940027941 immunoglobulin g Drugs 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 210000000440 neutrophil Anatomy 0.000 description 7
- 210000003720 plasmablast Anatomy 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 230000024704 B cell apoptotic process Effects 0.000 description 6
- 230000003844 B-cell-activation Effects 0.000 description 6
- 210000000612 antigen-presenting cell Anatomy 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 230000003442 weekly effect Effects 0.000 description 6
- 108091008875 B cell receptors Proteins 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 208000009386 Experimental Arthritis Diseases 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 5
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 5
- 239000004793 Polystyrene Substances 0.000 description 5
- 238000013103 analytical ultracentrifugation Methods 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000003915 cell function Effects 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 238000012512 characterization method Methods 0.000 description 5
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 210000001806 memory b lymphocyte Anatomy 0.000 description 5
- 230000009871 nonspecific binding Effects 0.000 description 5
- 229920002223 polystyrene Polymers 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 239000005018 casein Substances 0.000 description 4
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 4
- 235000021240 caseins Nutrition 0.000 description 4
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000002703 mutagenesis Methods 0.000 description 4
- 231100000350 mutagenesis Toxicity 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 239000012146 running buffer Substances 0.000 description 4
- 229940054269 sodium pyruvate Drugs 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 238000004448 titration Methods 0.000 description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 108090000672 Annexin A5 Proteins 0.000 description 3
- 102000004121 Annexin A5 Human genes 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 238000012286 ELISA Assay Methods 0.000 description 3
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 3
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 101000974353 Mus musculus Nuclear receptor coactivator 5 Proteins 0.000 description 3
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000003782 apoptosis assay Methods 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 235000013312 flour Nutrition 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 230000007837 negative regulation of B cell activation Effects 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000001542 size-exclusion chromatography Methods 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 101100476210 Caenorhabditis elegans rnt-1 gene Proteins 0.000 description 2
- 102100032768 Complement receptor type 2 Human genes 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
- 108091006020 Fc-tagged proteins Proteins 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 102220567143 Ornithine decarboxylase antizyme 1_F54Y_mutation Human genes 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 108010081690 Pertussis Toxin Proteins 0.000 description 2
- 101710138747 Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 102220471540 Single-stranded DNA cytosine deaminase_Y31H_mutation Human genes 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000012754 cardiac puncture Methods 0.000 description 2
- 230000011712 cell development Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 230000008482 dysregulation Effects 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000008629 immune suppression Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 208000018937 joint inflammation Diseases 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 231100000219 mutagenic Toxicity 0.000 description 2
- 230000003505 mutagenic effect Effects 0.000 description 2
- 230000014089 negative regulation of B cell differentiation Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 238000004091 panning Methods 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229940121503 tafasitamab Drugs 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 101150011571 BSL2 gene Proteins 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100027221 CD81 antigen Human genes 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 102220488661 Dimethylglycine dehydrogenase, mitochondrial_F29I_mutation Human genes 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 description 1
- 101001037147 Homo sapiens Immunoglobulin heavy variable 1-69 Proteins 0.000 description 1
- 101001047619 Homo sapiens Immunoglobulin kappa variable 3-20 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 102100040232 Immunoglobulin heavy variable 1-69 Human genes 0.000 description 1
- 102100022964 Immunoglobulin kappa variable 3-20 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108090000143 Mouse Proteins Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 102220592550 Neuroserpin_S52R_mutation Human genes 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108010010974 Proteolipids Proteins 0.000 description 1
- 102000016202 Proteolipids Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102220493341 Sodium/calcium exchanger 3_H34A_mutation Human genes 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102220504159 Testis-specific XK-related protein, Y-linked 2_N93Q_mutation Human genes 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 1
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 102220469752 Voltage-dependent L-type calcium channel subunit beta-2_G50D_mutation Human genes 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- GGKQIOFASHYUJZ-UHFFFAOYSA-N ametoctradin Chemical compound NC1=C(CCCCCCCC)C(CC)=NC2=NC=NN21 GGKQIOFASHYUJZ-UHFFFAOYSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 238000011948 assay development Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 238000013368 capillary electrophoresis sodium dodecyl sulfate analysis Methods 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 108010047295 complement receptors Proteins 0.000 description 1
- 102000006834 complement receptors Human genes 0.000 description 1
- 230000009827 complement-dependent cellular cytotoxicity Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012468 concentrated sample Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000003210 demyelinating effect Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 229950005015 inebilizumab Drugs 0.000 description 1
- 229940050282 inebilizumab-cdon Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000012004 kinetic exclusion assay Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 229950009756 loncastuximab Drugs 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 108010064578 myelin proteolipid protein (139-151) Proteins 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 108010087904 neutravidin Proteins 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000012510 peptide mapping method Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- 238000009522 phase III clinical trial Methods 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 230000003234 polygenic effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000029610 recognition of host Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 102220137600 rs112862820 Human genes 0.000 description 1
- 102200077165 rs118204021 Human genes 0.000 description 1
- 102220277465 rs1403203490 Human genes 0.000 description 1
- 102220125995 rs144185168 Human genes 0.000 description 1
- 102220286033 rs1553301271 Human genes 0.000 description 1
- 102200126997 rs17081389 Human genes 0.000 description 1
- 102200097265 rs199472846 Human genes 0.000 description 1
- 102200124819 rs28928899 Human genes 0.000 description 1
- 102220040213 rs587778234 Human genes 0.000 description 1
- 102220170950 rs769916550 Human genes 0.000 description 1
- 102220072337 rs794728990 Human genes 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000013389 whole blood assay Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR112022015902A BR112022015902A2 (en) | 2020-02-28 | 2021-02-22 | ANTI-HUMAN CD19 ANTIBODIES |
CR20220421A CR20220421A (en) | 2020-02-28 | 2021-02-22 | Anti-human cd19 antibodies |
JOP/2022/0204A JOP20220204A1 (en) | 2020-02-28 | 2021-02-22 | Anti-human cd19 antibodies |
MX2022010621A MX2022010621A (en) | 2020-02-28 | 2021-02-22 | Anti-human cd19 antibodies. |
CA3169155A CA3169155A1 (en) | 2020-02-28 | 2021-02-22 | Anti-human cd19 antibodies |
KR1020227029214A KR20220132579A (en) | 2020-02-28 | 2021-02-22 | anti-human CD19 antibody |
AU2021225792A AU2021225792A1 (en) | 2020-02-28 | 2021-02-22 | Anti-human CD19 antibodies |
JP2022551767A JP7450743B2 (en) | 2020-02-28 | 2021-02-22 | Anti-human CD19 antibody |
EP21712613.5A EP4110815A1 (en) | 2020-02-28 | 2021-02-22 | Anti-human cd19 antibodies |
PE2022001851A PE20221593A1 (en) | 2020-02-28 | 2021-02-22 | HUMAN ANTI-CD19 ANTIBODIES |
CN202180016785.XA CN115151570A (en) | 2020-02-28 | 2021-02-22 | Anti-human CD19 antibodies |
IL295494A IL295494A (en) | 2020-02-28 | 2021-02-22 | Anti-human cd19 antibodies |
CONC2022/0012212A CO2022012212A2 (en) | 2020-02-28 | 2022-08-26 | Human anti-CD19 antibodies |
DO2022000173A DOP2022000173A (en) | 2020-02-28 | 2022-08-26 | HUMAN ANTI-CD19 ANTIBODIES |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062983093P | 2020-02-28 | 2020-02-28 | |
US62/983,093 | 2020-02-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021173471A1 true WO2021173471A1 (en) | 2021-09-02 |
Family
ID=74885029
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2021/018989 WO2021173471A1 (en) | 2020-02-28 | 2021-02-22 | Anti-human cd19 antibodies |
Country Status (20)
Country | Link |
---|---|
US (1) | US11623956B2 (en) |
EP (1) | EP4110815A1 (en) |
JP (1) | JP7450743B2 (en) |
KR (1) | KR20220132579A (en) |
CN (1) | CN115151570A (en) |
AR (1) | AR121370A1 (en) |
AU (1) | AU2021225792A1 (en) |
BR (1) | BR112022015902A2 (en) |
CA (1) | CA3169155A1 (en) |
CL (1) | CL2022002329A1 (en) |
CO (1) | CO2022012212A2 (en) |
CR (1) | CR20220421A (en) |
DO (1) | DOP2022000173A (en) |
EC (1) | ECSP22067275A (en) |
IL (1) | IL295494A (en) |
JO (1) | JOP20220204A1 (en) |
MX (1) | MX2022010621A (en) |
PE (1) | PE20221593A1 (en) |
TW (1) | TWI790548B (en) |
WO (1) | WO2021173471A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023198744A1 (en) | 2022-04-13 | 2023-10-19 | Tessa Therapeutics Ltd. | Therapeutic t cell product |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202346359A (en) | 2022-04-15 | 2023-12-01 | 美商凱維那醫療公司 | Methods and compositions for treating autoimmune disease |
WO2023240064A1 (en) | 2022-06-08 | 2023-12-14 | Kyverna Therapeutics, Inc. | Methods and compositions for treating autoimmune disease |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007076950A1 (en) | 2005-12-30 | 2007-07-12 | Merck Patent Gmbh | Anti-cd19 antibodies with reduced immunogenicity |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2066349T3 (en) * | 2006-09-08 | 2012-07-09 | Medimmune Llc | HUMANIZED ANTI-CD19 ANTIBODIES AND USE THEREOF IN TREATMENT OF TUMORS, TRANSPLANTATION AND AUTOIMMUNE DISEASES |
AU2015255979B2 (en) | 2014-05-08 | 2019-11-21 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Using B-cell-targeting antigen IgG fusion as tolerogenic protein therapy for treating adverse immune responses |
JP7148504B2 (en) | 2016-06-08 | 2022-10-05 | ゼンコー,インコーポレイティド | Treatment of IgG4-related diseases with anti-CD19 antibodies cross-linked to CD32B |
-
2021
- 2021-02-18 AR ARP210100425A patent/AR121370A1/en unknown
- 2021-02-18 TW TW110105560A patent/TWI790548B/en active
- 2021-02-22 JO JOP/2022/0204A patent/JOP20220204A1/en unknown
- 2021-02-22 CA CA3169155A patent/CA3169155A1/en active Pending
- 2021-02-22 AU AU2021225792A patent/AU2021225792A1/en active Pending
- 2021-02-22 BR BR112022015902A patent/BR112022015902A2/en unknown
- 2021-02-22 IL IL295494A patent/IL295494A/en unknown
- 2021-02-22 WO PCT/US2021/018989 patent/WO2021173471A1/en active Application Filing
- 2021-02-22 EP EP21712613.5A patent/EP4110815A1/en active Pending
- 2021-02-22 PE PE2022001851A patent/PE20221593A1/en unknown
- 2021-02-22 JP JP2022551767A patent/JP7450743B2/en active Active
- 2021-02-22 KR KR1020227029214A patent/KR20220132579A/en active Search and Examination
- 2021-02-22 CR CR20220421A patent/CR20220421A/en unknown
- 2021-02-22 MX MX2022010621A patent/MX2022010621A/en unknown
- 2021-02-22 CN CN202180016785.XA patent/CN115151570A/en active Pending
- 2021-02-22 US US17/181,184 patent/US11623956B2/en active Active
-
2022
- 2022-08-25 CL CL2022002329A patent/CL2022002329A1/en unknown
- 2022-08-26 CO CONC2022/0012212A patent/CO2022012212A2/en unknown
- 2022-08-26 DO DO2022000173A patent/DOP2022000173A/en unknown
- 2022-08-26 EC ECSENADI202267275A patent/ECSP22067275A/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007076950A1 (en) | 2005-12-30 | 2007-07-12 | Merck Patent Gmbh | Anti-cd19 antibodies with reduced immunogenicity |
Non-Patent Citations (26)
Title |
---|
"NCBI", Database accession no. NP 001171569.1 |
A. LOYD ET AL.: "Remington: The Science and Practice of Pharmacy", 2012, PHARMACEUTICAL PRESS |
AL-LAZIKANI ET AL.: "Standard conformations for the canonical structures of immunoglobulins", JOURNAL OF MOLECULAR BIOLOGY, vol. 273, 1997, pages 927 - 948, XP004461383, DOI: 10.1006/jmbi.1997.1354 |
ANAL BIOCHEM, vol. 256, no. 2, 1998, pages 169 - 77 |
CARTER ET AL., IMMUNOL. RES., vol. 26, 2002, pages 45 - 54 |
CHOTHIA ET AL.: "Canonical structures for the hypervariable regions of immunoglobulins", JOURNAL OF MOLECULAR BIOLOGY, vol. 196, 1987, pages 901 - 917, XP024010426, DOI: 10.1016/0022-2836(87)90412-8 |
CREE ET AL., LANCET, vol. 394, no. 10206, 2019, pages 1352 - 1363 |
DARLINGBRAULT: "Kinetic Exclusion Assay Technology: Characterization of Molecular Interactions", ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES, vol. 2, 2005, pages 647 - 657, XP055396049, DOI: 10.1089/adt.2004.2.647 |
DEUTSCHER, METHODS IN ENZYMOLOGY, vol. 182, 1990, pages 83 - 89 |
J PHARM BIOMED ANAL, vol. 130, 2016, pages 3 - 18 |
JARACZEWSKA-BAUMANN ET AL.: "A Phase 1 b/2a Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XmAb@5871 in Patients with Rheumatoid Arthritis", EUROPEAN LEAGUE AGAINST RHEUMATISM (EULAR) 2015 ANNUAL MEETING POSTER, 12 June 2015 (2015-06-12), Retrieved from the Internet <URL:https://investors.xencor.com/static-files/0017dcfl-deb2-46eb-93ff-90bal64ec5Oc> |
JARACZEWSKA-BAUMANN ET AL.: "A Phase Ib/2a Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XmAb@5871 in Patients with Rheumatoid Arthritis", EULAR 2015 ANNUAL MEETING POSTER, 12 June 2015 (2015-06-12) |
JARACZEWSKA-BAUMANN ET AL.: "A Phase Ib/2a Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics ofXmAb®5871 in Patients with Rheumatoid Arthritis", EUROPEAN LEAGUE AGAINST RHEUMATISM (EULAR) 2015 ANNUAL MEETING POSTER, 12 June 2015 (2015-06-12), Retrieved from the Internet <URL:https://investors.xencor.com/static-files/0017dcf1-deb2-46eb-93ff-90ba164ec50c> |
JONATHAN ZALEVSKY ET AL: "The impact of Fc engineering on an anti-CD19 antibody: increased Fc gamma receptor affinity enhances B-cell clearing in nonhuman primates", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 113, no. 16, 16 April 2009 (2009-04-16), pages 3735 - 3743, XP002685051, ISSN: 0006-4971, [retrieved on 20081224], DOI: 10.1182/BLOOD-2008-10-182048 * |
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1991, NATIONAL INSTITUTES OF HEALTH |
KAPLON ET AL., MABS, vol. 12, no. 1, 2020, pages 1703531 |
KELLNER ET AL., LEUKEMIA, vol. 27, no. 7, 2013, pages 1595 - 1598 |
LABRIJN ET AL., NAT. BIOTECHNOL., vol. 27, no. 8, 2009, pages 767 |
LAWRENCE: "XmAb 5574, An Fc Engineered Humanized Anti-CD19 Monoclonal Antibody, Has Potent in Vitro and in Vivo Activities, and Has the Potential for Treating B Cell Malignancies | Blood | American Society of Hematology", 1 January 2008 (2008-01-01), XP055805140, Retrieved from the Internet <URL:https://ashpublications.org/blood/article/112/11/2621/60810/XmAbR5574-An-Fc-Engineered-Humanized-Anti-CD19> [retrieved on 20210518] * |
LEFRANC ET AL., NUCLEIC ACIDS RES, vol. 27, 1999, pages 209 - 212 |
NORTH ET AL.: "A New Clustering of Antibody CDR Loop Conformations", JOURNAL OF MOLECULAR BIOLOGY, vol. 406, 2011, pages 228 - 256, XP028129711, DOI: 10.1016/j.jmb.2010.10.030 |
PILAR BRITO-ZER?N ET AL: "IgG4-related disease: Advances in the diagnosis and treatment", BAILLIERE'S BEST PRACTICE AND RESEARCH. CLINICAL REUMATOLOGY, vol. 30, no. 2, 1 April 2016 (2016-04-01), GB, pages 261 - 278, XP055395374, ISSN: 1521-6942, DOI: 10.1016/j.berh.2016.07.003 * |
SCOPES: "Protein Purification: Principles and Practice", 1994, SPRINGER |
SEIDEL ET AL., MOL. THER., vol. 24, no. 9, 2016, pages 1634 - 43 |
SU S ET AL: "Review Article Anti-CD19 Monoclonal Antibodies: a New Approach to Lymphoma Therapy", IJMCM, vol. 4, no. 3, 1 January 2015 (2015-01-01), pages 143 - 151, XP055805142, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4644525/pdf/ijmcm-4-143.pdf> [retrieved on 20210518] * |
SZILI ET AL., MABS, vol. 6, no. 4, 2014, pages 991 - 999 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023198744A1 (en) | 2022-04-13 | 2023-10-19 | Tessa Therapeutics Ltd. | Therapeutic t cell product |
Also Published As
Publication number | Publication date |
---|---|
TW202146451A (en) | 2021-12-16 |
CN115151570A (en) | 2022-10-04 |
DOP2022000173A (en) | 2022-10-31 |
CA3169155A1 (en) | 2021-09-02 |
AR121370A1 (en) | 2022-06-01 |
US11623956B2 (en) | 2023-04-11 |
US20210269520A1 (en) | 2021-09-02 |
KR20220132579A (en) | 2022-09-30 |
ECSP22067275A (en) | 2022-09-30 |
JP2023515219A (en) | 2023-04-12 |
MX2022010621A (en) | 2022-11-30 |
BR112022015902A2 (en) | 2022-10-04 |
CR20220421A (en) | 2022-09-23 |
CO2022012212A2 (en) | 2022-09-09 |
JP7450743B2 (en) | 2024-03-15 |
PE20221593A1 (en) | 2022-10-10 |
IL295494A (en) | 2022-10-01 |
CL2022002329A1 (en) | 2023-04-10 |
TWI790548B (en) | 2023-01-21 |
EP4110815A1 (en) | 2023-01-04 |
AU2021225792A1 (en) | 2022-09-15 |
JOP20220204A1 (en) | 2023-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA3092064C (en) | Pd-1 agonist antibodies and uses thereof | |
CA2932966C (en) | Pd-1 antibody, antigen-binding fragment thereof, and medical use thereof | |
US11623956B2 (en) | Anti-human CD19 antibodies | |
CA3155275A1 (en) | Anti-cd47 antibodies and methods of use thereof | |
US11525005B2 (en) | Anti-CD40 antibody, antigen binding fragment thereof and medical use thereof | |
US20210009706A1 (en) | Anti-CD27 Antibody, Antigen-binding Fragment Thereof, and Medical Use Thereof | |
CN112969714A (en) | anti-CD 40 antibodies, antigen-binding fragments thereof, and medical uses thereof | |
WO2014028748A1 (en) | Interleukin 2 antibodies and antibody complexes | |
JPWO2016021621A1 (en) | Novel anti-human Igβ antibody | |
TW202246315A (en) | Compounds specific to coronavirus s protein and uses thereof | |
CN108473586B (en) | anti-CD 27 antibodies, antigen-binding fragments thereof, and medical uses thereof | |
RU2792748C2 (en) | Antibody to b7-h4, its antigen-binding fragment and its pharmaceutical use | |
RU2779128C2 (en) | Antibody to cd40, its antigene-binding fragment and its medical use | |
KR20170076332A (en) | Immunopotentiator containing anti-Ang2 antibody | |
WO2021175954A1 (en) | Antibodies having specificity for btnl8 and uses thereof | |
TW202144425A (en) | Specific antigen binding molecule, preparation method and pharmaceutical use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21712613 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3169155 Country of ref document: CA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112022015902 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 20227029214 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2022551767 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2021225792 Country of ref document: AU Date of ref document: 20210222 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021712613 Country of ref document: EP Effective date: 20220928 |
|
ENP | Entry into the national phase |
Ref document number: 112022015902 Country of ref document: BR Kind code of ref document: A2 Effective date: 20220811 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 522440334 Country of ref document: SA |